US Patent

US11992514 — Ready-to-use bivalirudin compositions

Formulation · Assigned to Maia Pharmaceuticals Inc · Expires 2039-05-20 · 13y remaining

Vulnerability score 55/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects ready-to-use liquid bivalirudin compositions that comprise a pharmaceutically acceptable amount of bivalirudin.

USPTO Abstract

Ready-to-use liquid bivalirudin compositions, methods of using the ready-to-use bivalirudin compositions, and methods of preparing the ready-to-use liquid bivalirudin compositions are provided herein. The liquid ready-to-use bivalirudin compositions comprise a pharmaceutically acceptable amount of bivalirudin.

Drugs covered by this patent

Patent Metadata

Patent number
US11992514
Jurisdiction
US
Classification
Formulation
Expires
2039-05-20
Drug substance claim
No
Drug product claim
Yes
Assignee
Maia Pharmaceuticals Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.